Moderna announced positive topline results from a Phase III trial with older adults and a vaccine candidate aimed at preventing respiratory syncytial virus.
https://www.pharmalive.com/wp-content/uploads/2022/10/ReutersModerna10-1-2022.jpg8001200BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-01-18 09:21:362023-01-18 09:21:36Moderna racks up Phase III RSV success